Stock News

Lonestar Resources US Inc. (LONE) Reaches $4.97 After 6.00% Down Move; Corcept Therapeutics (CORT)’s Sentiment Is 1.96

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.36 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 71.21 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

The stock of Lonestar Resources US Inc. (NASDAQ:LONE) is a huge mover today! The stock decreased 5.33% or $0.28 during the last trading session, reaching $4.97. About 264,623 shares traded or 179.50% up from the average. Lonestar Resources US Inc. (NASDAQ:LONE) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months negative chart setup for the $121.81 million company. It was reported on Jan, 14 by Barchart.com. We have $4.67 PT which if reached, will make NASDAQ:LONE worth $7.31M less.

The stock decreased 0.96% or $0.2 during the last trading session, reaching $20.65. About 1.32 million shares traded. Corcept Therapeutics Incorporated (CORT) has risen 124.81% since January 14, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Consonance Capital Management Lp holds 8.29% of its portfolio in Corcept Therapeutics Incorporated for 3.88 million shares. Ingalls & Snyder Llc owns 6.88 million shares or 6.92% of their US portfolio. Moreover, Tanaka Capital Management Inc has 6.02% invested in the company for 139,867 shares. The Ohio-based Shaker Investments Llc Oh has invested 1.53% in the stock. Globeflex Capital L P, a California-based fund reported 252,538 shares.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on March, 5. They expect $0.19 earnings per share, up 375.00% or $0.15 from last year’s $0.04 per share. CORT’s profit will be $21.69 million for 27.17 P/E if the $0.19 EPS becomes a reality. After $0.11 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 72.73% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 2 selling transactions for $283,125 activity.

Analysts await Lonestar Resources US Inc. (NASDAQ:LONE) to report earnings on March, 22. They expect $-0.17 EPS, up 96.87% or $5.26 from last year’s $-5.43 per share. After $-0.12 actual EPS reported by Lonestar Resources US Inc. for the previous quarter, Wall Street now forecasts 41.67% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *